Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Acquires Protein Firm Direvo

September 22, 2008 | A version of this story appeared in Volume 86, Issue 38

Bayer has acquired Direvo Biotech, a drug discovery firm specializing in protein engineering, in a cash deal valued at approximately $300 million. Direvo's technology platform has been applied to a range of proteins, including therapeutic antibodies and proteases that will be added to the preclinical pipeline of Bayer Schering Pharma. Direvo's Cologne, Germany, site will become a fourth center of biologics expertise for Bayer, which operates two other facilities in Germany and one in the U.S. Direvo's industrial biotechnology business has been sold to a group of investors, who will develop its expertise in the food, feed, and biorefinery markets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.